Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» immuno-oncology
immuno-oncology
Immuno-Oncology Treatments Finding Success with Combination Therapies
BioSpace
Thu, 03/25/21 - 11:44 am
immuno-oncology
Opdivo
Bristol-Myers Squibb
clinical trials
relatilimab
Ibrance
The year immuno-oncology could break into perioperative settings
EP Vantage
Tue, 01/26/21 - 12:00 am
Merck
Keytruda
breast cancer
immuno-oncology
perioperative breast cancer
Attacking pancreatic cancer with a novel immuno-oncology drug conjugate
Fierce Biotech
Mon, 11/9/20 - 09:04 pm
pancreatic cancer
antibody-drug conjugate
oncology
immuno-oncology
Agios helps identify genes that allow cancer to escape the immune system
Fierce Biotech
Thu, 09/24/20 - 10:18 am
CRISPR
cancer
Agios Pharmaceuticals
immuno-oncology
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
Fierce Biotech
Fri, 09/18/20 - 11:09 am
Alkermes
immuno-oncology
ESMO
ALKS 4230
Keytruda
Lava breaks prolonged silence with an $83M Series C and two I/O programs set for the clinic
Endpoints
Thu, 09/17/20 - 10:36 am
Lava
immuno-oncology
cancer bispecifics
China’s Junshi hits immuno-oncology milestone with breakthrough designation from FDA
MedCity News
Sat, 09/12/20 - 10:22 pm
China
Junshi Biosciences
immuno-oncology
toripalimab
nasopharyngeal carcinoma
FDA
After Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program
Fierce Biotech
Tue, 09/1/20 - 10:59 am
Jounce Therapeutics
Gilead Sciences
Bristol-Myers Squibb
biobucks
immuno-oncology
Eli Lilly Strikes $1 Billion Deal with Innovent for Checkpoint Inhibitor
BioSpace
Tue, 08/18/20 - 11:00 pm
Eli Lilly
Innovent Biologics
China
immuno-oncology
Merck KGaA picks up another anticancer bispecific from F-star
Fierce Biotech
Fri, 07/17/20 - 11:07 am
Merck KGaA
F-star Therapeutics
immuno-oncology
bispecific antibodies
AI startup Nucleai has immuno-oncology treatment failures in its sights
Pharmaforum
Tue, 07/7/20 - 08:09 pm
Nucleai
artificial intelligence
cancer
Debiopharm
immuno-oncology
Natural killer biotech Artiva launches with $78M, industry veterans
Fierce Biotech
Fri, 06/26/20 - 09:50 am
immuno-oncology
natural killer cell therapy
Artiva
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
Fierce Pharma
Thu, 06/25/20 - 08:36 pm
immuno-oncology
checkpoint inhibitors
Merck
Bristol-Meyers Squibb
COVID-19
Keytruda
Opidvo
Yervoy
Genentech
Tecentriq
AstraZeneca
Imfinzi
Gilead pens $1.5B buyout option deal for Pionyr
Fierce Biotech
Tue, 06/23/20 - 10:50 am
Gilead Sciences
Pionyr
M&A
immuno-oncology
GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track
Xconomy
Sat, 06/13/20 - 11:27 pm
GSK
oncology
Zejula
niraparib
belantamab mafodotin
dostarlimab
immuno-oncology
Scopus Bio preps trials of gene-silencing immuno-oncology drug
Pharmaforum
Fri, 06/12/20 - 10:56 am
Scopus BioPharma
lymphoma
immuno-oncology
CpG-STAT3siRNA
gene therapy
Bristol's Celgene merger sees it bounce Jounce drug pact
Fierce Biotech
Fri, 06/5/20 - 10:43 am
Bristol-Myers Squibb
Celgene
Jounce Therapeutics
M&A
immuno-oncology
Gilead pens $2B Arcus pact for immuno-oncology targets of the past and future
Fierce Biotech
Wed, 05/27/20 - 10:28 am
Gilead Sciences
ARCUS
immuno-oncology
One of the best connected biotech startups in Boston snags a plum discovery deal with Novartis
Endpoints
Wed, 04/15/20 - 10:39 am
Novartis
drug discovery
solid tumors
immuno-oncology
Boston
startups
TScan
NextCure Delays 2 Clinical Trials Due to Coronavirus
Motley Fool
Tue, 04/14/20 - 09:57 pm
NextCure
clinical trials
COVID-19
pandemic
immuno-oncology
NC318
NC410
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »